OABI · OmniAb Inc
AI read · Neutral
The AI's read
OmniAb jumped after revising FY26 cash guidance higher and signing a global collaboration and license with Eli Lilly for a new ion channel program. That company-specific news explains the sharp intraday move and is a real fundamental catalyst. The market has already moved hard. OABI is up roughly 17% intraday and trading near its 52-week high, so a lot of the headline upside looks priced. We lean NEUTRAL. The deal validates the story but upside appears limited and the broader market is in a choppy consolidation regime, so conviction for more upside is muted.